Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022
GAITHERSBURG, Md., Feb. 21, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter and full year 2021 financial results and operational highlights on Monday, February 28, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details: |
||
Date: |
February 28, 2022 |
|
Time: |
4:30 p.m. U.S. Eastern Standard Time (EST) |
|
Dial-in number: |
(877) 870-4263 (Domestic) or (412) 317-0790 (International) |
|
Webcast: |
||
• |
Participants will be prompted to request to join the Novavax, Inc. call. |
|
• |
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. |
|
Replay details: |
||
Date: |
Available starting at 7:30 p.m. EST, February 28, 2022 until 11:59 p.m. EST, March 7, 2022 |
|
Dial-in number: |
(877) 344-7529 (Domestic) or (412) 317-0088 (International) |
|
Passcode: |
2206365 |
|
Webcast: |
www.novavax.com/events, until May 28, 2022 |
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]
Solebury Trout
Alexandra Roy | 617-221-9197
[email protected]
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
[email protected]
SOURCE Novavax, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article